Comparative Pharmacology
Head-to-head clinical analysis: LORAZEPAM versus MENRIUM 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZEPAM versus MENRIUM 5 4.
LORAZEPAM vs MENRIUM 5-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity by increasing frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an anticholinergic that blocks muscarinic acetylcholine receptors.
2-3 mg orally or IV, 3-4 times daily; maximum 10 mg/day. For anxiety, 0.5-2 mg orally 2-3 times daily. For procedural sedation, IV: 0.044 mg/kg or 2 mg total, may repeat.
1 tablet (chlordiazepoxide 5 mg / clinidium bromide 2.5 mg) orally 3 to 4 times daily before meals and at bedtime. Maximum dose: 8 tablets per day.
None Documented
None Documented
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."
Clinical Note
moderateLorazepam + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Lorazepam."
Clinical Note
moderateLorazepam + Clemastine
Terminal elimination half-life is 12-18 hours. Clinically significant for once-daily dosing; may accumulate in elderly or hepatic impairment.
Chlordiazepoxide: Terminal half-life 5-30 hours (mean 10 hours), extended to 30-60 hours in elderly or hepatic impairment. Clidinium: Terminal half-life approximately 1-2 hours due to rapid clearance.
Primarily renal excretion as glucuronide conjugates; less than 1% excreted unchanged. Approximately 60-80% eliminated in urine, with 15-20% in feces.
Chlordiazepoxide: Renal excretion of unchanged drug (<1%) and conjugates (60-70%); fecal excretion (30-40%). Clidinium: Primarily renal elimination as unchanged drug and metabolites (50-70%), with biliary/fecal excretion (30-50%).
Category D/X
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Clemastine."